Search - tctmd.com

Displaying 1 - 2 of 2

Sort: Relevancy | Date

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

November 03, 2022

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

October 12, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.